#Japan #Tokyo #cancer screening #N-NOSE #HIROTSU BioScience

Revolutionizing Cancer Screening with N-NOSE

In a groundbreaking advancement for early cancer detection, HIROTSU Bioscience, headquartered in Tokyo, has redefined the sample submission process for its innovative cancer screening test, N-NOSE. This revolutionary test utilizes specialized nematodes to detect cancer by identifying distinct odors associated with the disease. The latest improvement enables users to submit their samples via postal service at room temperature, eliminating the previous requirement for refrigerated transportation. This user-friendly approach encourages widespread participation in cancer screening across Japan.

Enhancing Accessibility for All

To celebrate this launch, a press conference titled N-NOSE: Convenient New Submission Service for Comprehensive Cancer Screening was held at the Tokyo Garden Terrace Kioi Conference Center. HIROTSU's CEO, Takasuke Hirotsu, presented the new service, and special guest Toru Kazama, an actor and cancer survivor, shared his personal journey with cancer and the importance of early detection. The N-NOSE screening service allows users to assess their risk for 23 different types of cancer at an affordable price with a single test, significantly enhancing convenience for those who may have faced geographical or time-related barriers to traditional testing methods.

The incorporation of postal submissions aligns with the company’s vision of fostering a society where cancer detection is not viewed as a daunting experience but rather as a regular aspect of health maintenance. HIROTSU hopes that this service will promote regular health check-ups and establish a new routine for self-care among the populace.

Overview of the N-NOSE Service

1. Product Range:
- N-NOSE
- N-NOSE plus for pancreas
- N-NOSE plus for liver
- N-NOSE for recurrence check
- N-NOSE for dogs
- N-NOSE for cats

2. Service Launch Date:
- Commencing from August 22, 2025, at 12:00 PM for new purchases.

3. Submission Locations:
- Available nationwide through approximately 175,000 mailboxes managed by Japan Post, excluding certain remote islands.

Addressing Japan’s Cancer Crisis

According to the Ministry of Health, Labour and Welfare's demographic statistics, cancer is the leading cause of death in Japan, accounting for 25.6% of all fatalities. There is a notable disparity in cancer mortality rates across the country. For instance, Akita Prefecture has the highest rate, while Nagano Prefecture records the lowest. These variances are attributed to factors such as access to healthcare, lifestyle habits, and rates of medical screening.

Many individuals in rural areas face barriers such as limited access to healthcare facilities and transportation challenges that hinder them from getting screened for cancer. N-NOSE offers a convenient solution by allowing users to collect urine samples at home and mail them for testing, thus overcoming geographical limitations and promoting equitable access to cancer detection services.

Data from HIROTSU shows a significant increase in utilization of N-NOSE in regions with high cancer mortality rates, indicating a growing awareness and willingness to engage in preventive healthcare practices. The introduction of postal submissions is set to further dismantle the barriers posed by physical distance, making cancer screening more accessible to everyone in Japan.

Advanced Olfactory Technology for Early Detection

The science behind N-NOSE relies on the innate ability of nematodes—tiny organisms approximately 1mm in length—to detect specific odors associated with cancer. HIROTSU began developing this method over a decade ago, motivated by the desire to create a world where cancer can be detected early, thus safeguarding public health and ensuring future well-being.

Their dedication led to extensive clinical research over four years to validate the reliability of their technology. Today, HIROTSU collaborates with numerous research institutions and medical organizations, and their findings have been published in respected scientific journals, further bolstering the credibility of the N-NOSE test.

Making Cancer Screening Accessible

N-NOSE is designed to allow users to screen for risks of 23 different types of cancer using just a small urine sample. With over 800,000 tests conducted to date, N-NOSE has gained the trust of businesses, with 2,400 companies integrating the service as part of their employee wellness programs, highlighting its effectiveness and affordability.

There is no physical discomfort involved, making it a convenient option for people with busy lifestyles or financial concerns. Since its inception, HIROTSU has emphasized the importance of early cancer detection and preventive measures, thus fostering a greater awareness among the public.

About HIROTSU Bioscience

Established in 2016, HIROTSU Bioscience is committed to developing unique testing technologies that harness biological capabilities to safeguard public health and enhance future security. Their cornerstone product, N-NOSE, demonstrates the potential of biological detection methods in addressing societal challenges surrounding cancer, with millions now living longer and healthier lives due to these advancements.

For more information:

• - Corporate website: HIROTSU Bioscience
• - N-NOSE service site: N-NOSE
• - N-NOSE plus: N-NOSE plus
• - N-NOSE for pets: N-NOSE animals

HIROTSU Bioscience continues to lead the way in cancer detection technology, ensuring that early diagnosis and preventive care become standard components of health maintenance for everyone, regardless of location or situation.